Blocking cytokines, such as IFN-γ, with tofacitinib prevents inflammatory T cell activation, which effectively treats autoimmune disorders, such as rheumatoid arthritis, ulcerative colitis, and psoriasis (22–24). This evidence concerns the gene IFNG and rheumatoid arthritis.